Eplontersen,Inotersen
Ionis Pharmaceuticals,Akcea Therapeutics,Astrazeneca
['bridge bio']
bcbn feed: neuro-ttransform phase iii results presented at aan showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks: ... #boston #biotech 
Boston Cambridge Biotech Networks: Building a community and providing news and events for the local life science industry. For jobs follow @bcbnjobs